The United States and United Kingdom Establish Duty-Free Pact on Drugs.

The United Kingdom and the United States have hammered out a key trade agreement that will preserve no levies on British medicine shipments going into the American market.

Key Provisions of the Accord

In exchange for the tariff guarantee, the UK has pledged to increase expenditure on drugs through the National Health Service (NHS). This commitment ensures that duties on these crucial goods will stay at nothing for a period of three years.

This agreement is in response to recent threats to dramatically increase duties on branded drug products, with figures mentioned as high as double the cost.

"This deal with the United Kingdom reinforces the global environment for innovative medicines and brings long-overdue balance to transatlantic medicine commerce," a release said.

Trade Importance

Drugs are one of the UK's largest exports to the US, which is by far the primary destination for large British pharmaceutical firms.

Statistics reveal that in the 12 months prior to September, the UK exported medicines totaling billions to the US. This amount made up 17.4% of total UK exports in that span.

"This guarantee secures employment, boosts capital expenditure and sets the stage for the UK to become a international leader for medical research," a minister remarked.

Key British Pledges

The deal entails several specific commitments from the British government:

• Higher Cost Ceiling: The UK will increase the cost ceiling at which it judges new medicines to be prohibitively costly by a quarter.
• Higher Drug Budget: There is a aim to raise total health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
• Rebate Cap: The percentage manufacturers must refund to the NHS to prevent overspending will be restricted at fifteen percent. Last year, rebates were more than 20%.

Industry Background

The pact comes amid a long-running row between the drug companies and the British authorities over spending levels and NHS adoption.

The disagreement were intensified by claims that US customers were charged a premium for the equivalent treatments than patients in the Britain and the EU.

Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or abandoned, while substantial expansions have been directed toward projects in the United States.

One official publicly accepted that the NHS needed to invest a greater share on treatments, noting that its expenditure on drugs had shrunk as a proportion of its resources over the last ten years.